Tacrolimus for children with refractory nephrotic syndrome: a one-year prospective, multicenter, and open-label study of Tacrobell®, a generic formula

详细信息    查看全文

• 作者：Eun Mi Yang ; Sang Taek Lee ; Hyun Jin Choi ; Hee Yeon Cho…
• 关键词：generic drugs ; nephrotic syndrome ; tacrolimus
• 刊名：World Journal of Pediatrics
• 出版年：2016
• 出版时间：February 2016
• 年：2016
• 卷：12
• 期：1
• 页码：60-65
• 全文大小：579 KB
• 参考文献：1.Tarshish P, Tobin JN, Bernstein J, Edelmann CM Jr. Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children. J Am Soc Nephrol 1997;8:769–776.PubMed
  2.Hodson EM, Willis NS, Craig JC. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev 2007;(4):CD001533.
  3.Kyrieleis HA, Löwik MM, Pronk I, Cruysberg HR, Kremer JA, Oyen WJ, et al. Long-term outcome of biopsy-proven, frequently relapsing minimal-change nephrotic syndrome in children. Clin J Am Soc Nephrol 2009;4:1593–1600.PubMed PubMedCentral CrossRef
  4.Martinelli R, Okumura AS, Pereira LJ, Rocha H. Primary focal segmental glomerulosclerosis in children: prognostic factors. Pediatr Nephrol 2001;16:658–661.PubMed CrossRef
  5.Oh J, Kemper MJ. Second-line options for refractory steroidsensitive and -resistant nephrotic syndrome. Expert Rev Clin Pharmacol 2010;3:527–537.PubMed CrossRef
  6.Latta K, von Schnakenburg C, Ehrich JH. A meta-analysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children. Pediatr Nephrol 2001;16:271–282.PubMed CrossRef
  7.Choudhry S, Bagga A, Hari P, Sharma S, Kalaivani M, Dinda A. Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: a randomized controlled trial. Am J Kidney Dis 2009;53:760–769.PubMed CrossRef
  8.Iijima K, Hamahira K, Tanaka R, Kobayashi A, Nozu K, Nakamura H, et al. Risk factors for cyclosporine-induced tubulointerstitial lesions in children with minimal change nephrotic syndrome. Kidney Int 2002;61:1801–1805.PubMed CrossRef
  9.Westhoff TH, Schmidt S, Zidek W, Beige J, van der Giet M. Tacrolimus in steroid-resistant and steroid-dependent nephrotic syndrome. Clin Nephrol 2006;65:393–400.PubMed CrossRef
  10.Loeffler K, Gowrishankar M, Yiu V. Tacrolimus therapy in pediatric patients with treatment-resistant nephrotic syndrome. Pediatr Nephrol 2004;19:281–287.PubMed CrossRef
  11.Denton MD, Magee CC, Sayegh MH. Immunosuppressive strategies in transplantation. Lancet 1999;353:1083–1091.PubMed CrossRef
  12.Wang W, Xia Y, Mao J, Chen Y, Wang D, Shen H, et al. Treatment of tacrolimus or cyclosporine A in children with idiopathic nephrotic syndrome. Pediatr Nephrol 2012;27:2073–2079.PubMed CrossRef
  13.Trompeter R, Filler G, Webb NJ, Watson AR, Milford DV, Tyden G, et al. Randomized trial of tacrolimus versus cyclosporin microemulsion in renal transplantation. Pediatr Nephrol 2002;17:141–149.PubMed CrossRef
  14.McCauley J, Tzakis AG, Fung JJ, Todo S, Starzl TE. FK 506 in steroid-resistant focal sclerosing glomerulonephritis of childhood. Lancet 1990;335:674.PubMed CrossRef
  15.McCauley J, Shapiro R, Ellis D, Igdal H, Tzakis A, Starzl TE. Pilot trial of FK 506 in the management of steroid-resistant nephrotic syndrome. Nephrol Dial Transplant 1993;8:1286–1290.PubMed PubMedCentral
  16.Park K, Kim YS, Kwon KI, Park MS, Lee YJ, Kim KH. A randomized, open-label, two-period, crossover bioavailability study of two oral formulations of tacrolimus in healthy Korean adults. Clin Ther 2007;29:154–162.PubMed CrossRef
  17.Schwartz GJ, Muñoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol 2009;20:629–637.PubMed PubMedCentral CrossRef
  18.Kim SJ, Huh KH, Han DJ, Moon IS, Kim SJ, Kim YL, et al. A 6-month, multicenter, single-arm pilot study to evaluate the efficacy and safety of generic tacrolimus (TacroBell) after primary renal transplantation. Transplant Proc 2009;41:1671–1674.PubMed CrossRef
  19.Hwang H, Ghee JY, Song JH, Piao S, Yang CW. Comparison of adverse drug reaction profiles of two tacrolimus formulations in rats. Immunopharmacol Immunotoxicol 2012;34:434–442.PubMed CrossRef
  20.Pennesi M, Gagliardo A, Minisini S. Effective tacrolimus treatment in a child suffering from severe nephrotic syndrome. Pediatr Nephrol 2003;18:477–478.PubMed
  21.Xie G, Xu J, Ye C, Chen D, Xu C, Yang L, et al. Immunosuppressive treatment for nephrotic idiopathic membranous nephropathy: a meta-analysis based on Chinese adults. PLoS One 2012;7:e44330.
  22.Bhimma R, Adhikari M, Asharam K, Connolly C. Management of steroid-resistant focal segmental glomerulosclerosis in children using tacrolimus. Am J Nephrol 2006;26:544–551.PubMed CrossRef
  23.Kim J, Patnaik N, Chorny N, Frank R, Infante L, Sethna C. Second-line immunosuppressive treatment of childhood nephrotic syndrome: a single-center experience. Nephron Extra 2014;4:8–17.PubMed PubMedCentral CrossRef
  24.Gulati A, Sinha A, Gupta A, Kanitkar M, Sreenivas V, Sharma J, et al. Treatment with tacrolimus and prednisolone is preferable to intravenous cyclophosphamide as the initial therapy for children with steroid-resistant nephrotic syndrome. Kidney Int 2012;82:1130–1135.PubMed CrossRef
  25.Chamienia A, Biedunkiewicz B, Król E, Debska-Slizien A, Rutkowski B. One-year observation of kidney allograft recipients converted from cyclosporine microemulsion to tacrolimus. Transplant Proc 2006;38:81–85.PubMed CrossRef
  26.Falkiewicz K, Kaminska D, Nahaczewska W, Boratynska M, Owczarek H, Klinger M, et al. Renal function and tubular phosphate handling in long-term cyclosporine-and tacrolimusbased immunosuppression in kidney transplantation. Transplant Proc 2006;38:119–122.PubMed CrossRef
  27.Sinha MD, MacLeod R, Rigby E, Clark AG. Treatment of severe steroid-dependent nephrotic syndrome (SDNS) in children with tacrolimus. Nephrol Dial Transplant 2006;21:1848–1854.PubMed CrossRef
  28.Dittrich K, Knerr I, Rascher W, Dötsch J. Transient insulindependent diabetes mellitus in children with steroid-dependent idiopathic nephrotic syndrome during tacrolimus treatment. Pediatr Nephrol 2006;21:958–961.PubMed CrossRef
  29.Gulati S, Prasad N, Sharma RK, Kumar A, Gupta A, Baburaj VP. Tacrolimus: a new therapy for steroid-resistant nephrotic syndrome in children. Nephrol Dial Transplant 2008;23:910–913.PubMed CrossRef
  30.Webster A, Woodroffe RC, Taylor RS, Chapman JR, Craig JC. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev 2005;(4):CD003961.
  31.Chen W, Liu Q, Liao Y, Yang Z, Chen J, Fu J, et al. Outcomes of tacrolimus therapy in adults with refractory membranous nephrotic syndrome: a prospective, multicenter clinical trial. Am J Med Sci 2013;345:81–87.PubMed CrossRef
  32.Al-Uzri A, Stablein DM, ACohn R. Posttransplant diabetes mellitus in pediatric renal transplant recipients: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Transplantation 2001;72:1020–1024.PubMed CrossRef
  33.Burroughs TE, Swindle JP, Salvalaggio PR, Lentine KL, Takemoto SK, Bunnapradist S, et al. Increasing incidence of new-onset diabetes after transplant among pediatric renal transplant patients. Transplantation 2009;88:367–373.PubMed PubMedCentral CrossRef
  34.Dötsch J, Dittrich K, Plank C, Rascher W. Is tacrolimus for childhood steroid-dependent nephrotic syndrome better than ciclosporin A? Nephrol Dial Transplant 2006;21:1761–1763.PubMed CrossRef
  35.van Hooff JP, Christiaans MH, van Duijnhoven EM. Tacrolimus and posttransplant diabetes mellitus in renal transplantation. Transplantation 2005;79:1465–1469.PubMed CrossRef
  36.Boots JM, van Duijnhoven EM, Christiaans MH, Wolffenbuttel BH, van Hooff JP. Glucose metabolism in renal transplant recipients on tacrolimus: the effect of steroid withdrawal and tacrolimus trough level reduction. J Am Soc Nephrol 2002;13:221–227.PubMed
  
• 作者单位：Eun Mi Yang (1) (2)
  Sang Taek Lee (3)
  Hyun Jin Choi (2)
  Hee Yeon Cho (3)
  Joo Hoon Lee (4)
  Hee Gyung Kang (2) (5)
  Young Seo Park (4) (5)
  Hae Il Cheong (6)
  Il-Soo Ha (2) (6)
  
  1. Department of Pediatrics, Chonnam National University Hospital, Gawngju, Korea
  2. Department of Pediatrics, Seoul National University Children’s Hospital, Seoul, Korea
  3. Department of Pediatrics, Samsung Medical Center, Sungkynkwan University School of Medicine, Seoul, Korea
  4. Department of Pediatrics, Asan Medical Center Children’s Hospital, University of Ulsan College of Medicine, Seoul, Korea
  5. Research Coordination Center for Rare Diseases, Seoul National University Hospital, Seoul, Korea
  6. Kidney Research Institute, Medical Research Center, Seoul National University College of Medicine, Seoul, Korea
  
• 刊物主题：Pediatrics; Pediatric Surgery; Maternal and Child Health; Intensive / Critical Care Medicine; Surgery; Imaging / Radiology;
• 出版者：Springer Berlin Heidelberg
• ISSN：1867-0687

文摘

Background Cyclosporine A and tacrolimus (TAC) are often used as a second-line treatment for children with refractory nephrotic syndrome (NS). This study was undertaken to investigate the efficacy and safety of Tacrobell®, a locally produced generic form of TAC.